FRM
Fox Run Management’s Acadia Pharmaceuticals ACAD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-31,938
| Closed | -$530K | – | 817 |
|
|
2025
Q1 | $530K | Buy |
31,938
+6,516
| +26% | +$108K | 0.08% | 462 |
|
|
2024
Q4 | $466K | Buy |
+25,422
| New | +$466K | 0.08% | 459 |
|
|
2024
Q3 | – | Sell |
-20,302
| Closed | -$330K | – | 767 |
|
|
2024
Q2 | $330K | Buy |
+20,302
| New | +$330K | 0.06% | 537 |
|
|
2023
Q4 | – | Sell |
-23,477
| Closed | -$489K | – | 692 |
|
|
2023
Q3 | $489K | Buy |
+23,477
| New | +$489K | 0.14% | 270 |
|
|
2023
Q2 | – | Sell |
-63,707
| Closed | -$1.2M | – | 650 |
|
|
2023
Q1 | $1.2M | Buy |
+63,707
| New | +$1.2M | 0.39% | 30 |
|
|
2022
Q4 | – | Sell |
-14,920
| Closed | -$244K | – | 585 |
|
|
2022
Q3 | $244K | Buy |
14,920
+4,843
| +48% | +$79.2K | 0.09% | 422 |
|
|
2022
Q2 | $142K | Sell |
10,077
-14,023
| -58% | -$198K | 0.07% | 447 |
|
|
2022
Q1 | $584K | Buy |
+24,100
| New | +$584K | 0.33% | 63 |
|
|
2021
Q4 | – | Sell |
-12,027
| Closed | -$200K | – | 443 |
|
|
2021
Q3 | $200K | Sell |
12,027
-950
| -7% | -$15.8K | 0.13% | 390 |
|
|
2021
Q2 | $317K | Buy |
+12,977
| New | +$317K | 0.29% | 150 |
|
|
2020
Q3 | – | Sell |
-6,958
| Closed | -$334K | – | 158 |
|
|
2020
Q2 | $334K | Buy |
+6,958
| New | +$334K | 0.44% | 82 |
|
|
2019
Q4 | – | Sell |
-12,390
| Closed | -$446K | – | 366 |
|
|
2019
Q3 | $446K | Buy |
+12,390
| New | +$446K | 0.41% | 57 |
|
|
2018
Q3 | – | Sell |
-25,822
| Closed | -$394K | – | 540 |
|
|
2018
Q2 | $394K | Buy |
+25,822
| New | +$394K | 0.13% | 336 |
|
|
2017
Q2 | – | Sell |
-21,600
| Closed | -$743K | – | 610 |
|
|
2017
Q1 | $743K | Buy |
21,600
+10,200
| +89% | +$351K | 0.3% | 72 |
|
|
2016
Q4 | $329K | Buy |
+11,400
| New | +$329K | 0.17% | 257 |
|